ASTRAZENECA PLC reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge
SEC filing record 1 source field available
Fiscal year end
31 December
ASTRAZENECA PLC has filed 2,050 SEC EDGAR filings since 13 Mar 1995

SEC filing history

Showing 676-700 of 1,000 matching filings.

Per page
25
Current page
28
6-K File 001-11960

IMFINZI + TREMELIMUMAB SHOWED SURVIVAL IN POSEIDON

Filing date
07 May 2021
Reporting date
07 May 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
425

425

Filing date
06 May 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
425

425

Filing date
05 May 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
04 May 2021
Reporting date
04 May 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FARXIGA APPROVED IN THE US FOR CKD

Filing date
04 May 2021
Reporting date
04 May 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
425

425

Filing date
30 Apr 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
425

425

Filing date
30 Apr 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
425

425

Filing date
30 Apr 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

AZN: FIRST QUARTER 2021 RESULTS

Filing date
30 Apr 2021
Reporting date
30 Apr 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
425

425

Filing date
29 Apr 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

NIRSEVIMAB PHASE III TRIAL MET PRIMARY ENDPOINT

Filing date
26 Apr 2021
Reporting date
26 Apr 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TAGRISSO ADJUVANT RECEIVES POSITIVE CHMP OPINION

Filing date
26 Apr 2021
Reporting date
26 Apr 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

SELUMETINIB RECOMMENDED FOR EU APPROVAL IN NF1

Filing date
26 Apr 2021
Reporting date
26 Apr 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
425

425

Filing date
16 Apr 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
425

425

Filing date
16 Apr 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

US CLEARANCE OF PROPOSED ACQUISITION OF ALEXION

Filing date
16 Apr 2021
Reporting date
16 Apr 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TAGRISSO APPROVED IN CHINA IN EARLY LUNG CANCER

Filing date
14 Apr 2021
Reporting date
14 Apr 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
424B3 File 333-253315

424B3

Filing date
13 Apr 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-253315

EFFECT filing

Filing date
12 Apr 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
425

425

Filing date
12 Apr 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FORM 6-K

Filing date
12 Apr 2021
Reporting date
12 Apr 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

CIRCULAR AND NOTICE OF GENERAL MEETING

Filing date
12 Apr 2021
Reporting date
12 Apr 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
425

425

Filing date
12 Apr 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

UPDATE ON FARXIGA COVID-19 DARE-19 PHASE III TRIAL

Filing date
12 Apr 2021
Reporting date
12 Apr 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
F-4/A File 333-253315

F-4/A

Filing date
09 Apr 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .